Research Article

Soluble Interleukin-2 Receptor: A Potential Marker for Monitoring Disease Activity in IgG4-Related Disease

Table 1

Characteristics of patients with IgG4-RD.

SexAgeDisease manifestation of IgG4-RDIgG4 before treatmentsIL-2R before treatmentTreatment/comments

1M53Orbit and lymph nodes17.73695Rx: prednisone
2M36Salivary gland3.183441Rx: initially prednisone and Aza, later RTX
3M42Lymph nodes and kidney3.012,400Rx: prednisone and RTX, now CellCept
4M60Orbit and lymph nodes5.223700Rx: prednisone and MTX
5F46Orbit2.763400Rx: now infliximab
6M61Orbit, lymph node, and prostate13.485800sIL-2R initially measured under low-dose prednisone but active disease. Now prednisone and MTX
7M57Orbit, lymph node, and prostate and pancreas13.405151Rx: prednisone
8M63Orbit, pancreas, ENT, and prostate1.655700Rx: prednisone
9M17Lung, lymph nodes, and brain10.303900Rx: prednisone and RTX
10M53Mesenteric manifestation25.255900Rx: prednisone and RTX
11M32Pericardial and pleural manifestation5.403500Rx: prednisone
12M39Orbit1.658135Rx: prednisone and Aza
13M29Lymph node (Kimura disease)1.173800Patient declined treatment
14M55Hypophysis and ENT1.573100Rx: prednisone
15M48Mesenteric manifestation3.0114,027Patient did not show up for follow-up/treatment
16F52Orbit0.612859Surgical resection periorbital mass, no systemic treatment
17M61Biliary tract and ENT5.555300Rx: prednisone
18M79Lymph node42.89000Only lymph node manifestation, no systemic treatment
19F39Salivary gland3.973374Rx: prednisone
20M74Orbit and lymph node8.826135Rx: dexamethasone
21F52Orbit and lymph node3.272639Rx: prednisone
22M74Orbit and ENT3.307977Status after ocular surgery, currently no systemic treatment
23F61Orbit and ENT0.364182Rx: prednisone
24M65Retroperitoneal fibrosis3.447100Rx: prednisone
25M53Orbit and ENT1.454105Rx: prednisone, MTX, and now RTX
26F59Skin1.1810,800Rx: prednisone and Plaquenil

Characteristics of patients with IgG4-RD, including serum IgG4 and serum sIL-2R before treatment. P = patient; Rx = treatment; MTX = methotrexate; Aza = azathioprine; RTX = rituximab, NA = not applicable; NM = not measured. Normal range of serum IgG4 is 0.08–1.40 g/l, and normal range of serum sIL-2R is below 2500 pg/ml.